GlycA as a Novel Biomarker of Systemic Inflammation in Hypothyroidism
Authors' conclusion
Patients with IT, both OT and UT, had higher GlycA levels, which may be associated with low-grade systemic inflammation and, possibly, increased cardiovascular risk.
Study context
- Population
- ELSA-Brasil participants with serum TSH and GlycA measurements; excluded endogenous hyperthyroidism and drugs impacting thyroid function345 on levothyroxine (LT4)
- Participants
- 4,745 participants
- Exposure
- GlycA levels by thyroid status: euthyroid, undiagnosed hypothyroidism and LT4-treated (adequately, over- or under-treated)
- Undiagnosed hypothyroidism (UH)n = 467
- Adequately treated (AT)n = 213
- Outcome
- GlycA levels (magnetic resonance spectroscopy)
- Follow-up
- Baseline
Methodological detailsbaseline data from the ELSA-Brasil cohort study
- Baseline data from the ELSA-Brasil cohort study
Main finding
As reported in the abstract
GlycA
P < 0.01
Observational data: associations, not effects.
Further findings
| Outcome | Values | OR (CI) | |
|---|---|---|---|
| Higher GlycA with IT, multivariable analysisITvs EUMultivariable analysis | 1.53 (1.03–2.31) | ||
| 0.512Odds ratio (log scale) |
| Outcome | Values | P value |
|---|---|---|
| Prevalence of UH | UH 9.8% | |
| Adequately treated among those on LT4 | AT 61.7% | |
| GlycA, TPO-Ab+ subgroupIT vs EU · IT and UH higher vs euthyroidism | IT 423 μmol/L · UH 424 μmol/L · EU 402 μmol/L | P = 0.04 |
| GlycA by LT4 treatment adequacyAT vs OT · lower with AT | AT 405 μmol/L · OT 432 μmol/L · UT 423 μmol/L | 0.04 |
| GlycA by LT4 treatment adequacyAT vs UT · lower with AT | P = 0.02 |
Original publication
GlycA as a Novel Biomarker of Systemic Inflammation in Hypothyroidism. Thyroid. Published 22 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →